Related Parties |
3 Months Ended |
---|---|
Mar. 31, 2024 | |
Related Party Transactions [Abstract] | |
Related Parties | 15. Related Parties As of March 31, 2024 and December 31, 2023, Pfizer held 27,349,211 shares of our common stock and had nominated two members to our board of directors. For information related to our license agreement with Pfizer, please read Note 4, Pfizer License Agreement, to these unaudited condensed consolidated financial statements. As of March 31, 2024 and December 31, 2023, Bain Investor held 65,679,781 shares of our common stock and had nominated six members to our board of directors, with two such representatives that were required to be independent and were subject to Pfizer’s prior written consent. NDA Filing Support Services In January 2024, we entered into an agreement with Pfizer pursuant to which Pfizer will provide us with New Drug Application (NDA) filing support services consisting of data and document sharing, submission package support and report generation. As of March 31, 2024, $0.2 million of expenses have been incurred pursuant to this agreement. All such expenses incurred are included in accrued expenses and other liabilities and accounts payable as of March 31, 2024. Research Collaboration and License Agreement In June 2022, we entered into a research collaboration and license agreement with Pfizer, pursuant to which we will collaborate to identify, screen and evaluate compounds directed at certain targets for neuroscience diseases using Pfizer’s chemical library. Under the terms of the agreement, we will be required to reimburse Pfizer for certain research services and make a contingent development milestone payment and single-digit royalty payments on net sales of products containing one or more compounds derived from the collaboration. No amounts have been incurred under the agreement to date. Funding Agreement In April 2021, we entered into a funding agreement with Bain, pursuant to which Bain committed to provide $62.5 million in funding (the Bain Funding Commitment) to support our development of tavapadon for the treatment of Parkinson’s disease over four years, of which approximately $15.5 million (25% of the Bain Funding Commitment, net of $0.1 million of fees incurred by Bain) was received in April 2021, approximately $18.8 million (30% of the Bain Funding Commitment) was received in April 2022, approximately $15.6 million (25% of the Bain Funding Commitment) was received in April 2023, and approximately $12.5 million (20% of the Bain Funding Commitment) was received in April 2024. For additional information related to our funding agreement with Bain, please read Note 5, Financing Liabilities, to these unaudited condensed consolidated financial statements. Management Agreement Following the closing of the business combination in October 2020 pursuant to which ARYA Sciences Acquisition Corp II (ARYA) acquired Cerevel Therapeutics, Inc., with Cerevel Therapeutics, Inc. becoming a wholly-owned subsidiary of ARYA and ARYA being renamed Cerevel Therapeutics Holdings, Inc. (the Business Combination), we entered into a management agreement with Bain Capital Private Equity, LP and Bain Capital Life Sciences, LP, providing for the expense reimbursement and indemnification of such entities. No amounts have been incurred under the management agreement to date. For additional information related to the Business Combination, please read Note 3, Business Combination, to our audited consolidated financial statements included in our Annual Report. |